Prognostic impact of <i>ALK</i> rearrangement in surgically treated stage I lung adenocarcinoma: a retrospective cohort study.

However, in the stage IB subgroup (n=26), the DFS benefit did not reach statistical significance (HR =0.21; 95% CI: 0.02–1.84), leaving the efficacy of ALK -TKIs in stage I disease inconclusive and in need of further prospective validation in larger cohort.

also in 111,027 other papers

Younger patients (<60 years) and never-smokers also showed a trend toward higher ALK positivity, though the differences were not statistically significant.

also in 53,322 other papers